See more : Kelsian Group Limited (CY4.F) Income Statement Analysis – Financial Results
Complete financial analysis of Avadel Pharmaceuticals plc (AVDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avadel Pharmaceuticals plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Medialink Group Limited (2230.HK) Income Statement Analysis – Financial Results
- Fanli Digital Technology Co.,Ltd (600228.SS) Income Statement Analysis – Financial Results
- Sea & Land Integrated Corp. (5603.TWO) Income Statement Analysis – Financial Results
- Starboard Value Acquisition Corp. (SVACU) Income Statement Analysis – Financial Results
- Caleffi S.p.A. (CLF.MI) Income Statement Analysis – Financial Results
Avadel Pharmaceuticals plc (AVDL)
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96M | 0.00 | 0.00 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M | 26.10M | 32.60M | 37.09M | 42.12M | 38.62M | 36.65M | 23.02M | 23.60M | 55.41M | 25.17M | 18.41M | 13.09M | 10.90M | 11.04M | 9.52M | 8.10M | 4.90M |
| Cost of Revenue | 846.00K | 1.49M | 815.00K | 5.74M | 12.13M | 17.52M | 16.30M | 13.25M | 10.92M | 3.38M | 4.35M | 5.86M | 6.28M | 6.91M | 10.12M | 9.62M | 17.32M | 6.25M | 2.53M | 3.60M | 3.68M | 2.37M | 2.17M | 1.75M | 2.09M | 3.53M | 3.10M | 400.00K |
| Gross Profit | 27.12M | -1.49M | -815.00K | 16.59M | 47.09M | 85.75M | 156.44M | 137.00M | 162.29M | 11.39M | 18.09M | 20.24M | 26.32M | 30.18M | 32.00M | 29.00M | 19.33M | 16.77M | 21.07M | 51.81M | 21.49M | 16.03M | 10.92M | 9.15M | 8.95M | 5.99M | 5.00M | 4.50M |
| Gross Profit Ratio | 96.97% | 0.00% | 0.00% | 74.29% | 79.52% | 83.04% | 90.56% | 91.18% | 93.69% | 77.10% | 80.62% | 77.55% | 80.72% | 81.36% | 75.98% | 75.09% | 52.75% | 72.85% | 89.30% | 93.50% | 85.39% | 87.11% | 83.45% | 83.95% | 81.10% | 62.90% | 61.73% | 91.84% |
| Research & Development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M | 39.33M | 34.22M | 34.61M | 25.61M | 17.30M | 26.69M | 26.12M | 25.09M | 28.69M | 30.42M | 36.25M | 43.56M | 38.23M | 47.30M | 35.36M | 20.22M | 12.24M | 10.66M | 9.79M | 11.05M | 10.61M | 10.10M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M | 100.36M | 58.86M | 44.18M | 21.71M | 15.70M | 13.31M | 14.15M | 10.81M | 11.33M | 13.34M | 12.91M | 16.63M | 17.38M | 14.54M | 7.61M | 5.97M | 4.02M | 3.41M | 3.46M | 3.69M | 3.63M | 3.20M | 12.60M |
| Other Expenses | 0.00 | 3.35M | 217.00K | 406.00K | 816.00K | 1.90M | 2.09M | -6.55M | 0.00 | -36.00K | 573.00K | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 164.97M | 95.22M | 85.60M | 53.25M | 63.92M | 146.31M | 96.74M | 92.68M | 59.88M | 44.75M | 39.99M | 40.27M | 35.90M | 40.02M | 43.75M | 49.16M | 60.18M | 55.61M | 61.84M | 42.97M | 26.19M | 16.26M | 14.08M | 25.26M | 15.95M | 15.28M | 14.00M | 13.50M |
| Cost & Expenses | 165.81M | 95.22M | 85.60M | 59.00M | 76.04M | 163.82M | 113.04M | 105.93M | 70.81M | 48.13M | 44.34M | 46.13M | 42.18M | 46.93M | 53.87M | 58.78M | 77.50M | 61.86M | 64.37M | 46.58M | 29.87M | 18.63M | 16.24M | 27.01M | 18.04M | 18.81M | 17.10M | 13.90M |
| Interest Income | 0.00 | 11.12M | 2.13M | 12.59M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 963.00K | 254.00K | 629.00K | 667.00K | 464.00K | 525.00K | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M | 10.62M | 1.05M | 963.00K | 6.30M | 9.27M | 4.35M | 118.00K | 73.00K | 24.00K | 100.00K | 18.00K | 16.00K | 35.00K | 68.00K | 45.00K | 29.00K | 49.00K | 52.00K | 51.00K | 0.00 | 95.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.77M | 1.49M | 815.00K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700.00K | 900.00K |
| EBITDA | -149.13M | -97.60M | -84.78M | -34.97M | -23.61M | -95.15M | 65.89M | 5.73M | 115.54M | -94.74M | -50.03M | -8.36M | -5.16M | -4.05M | -5.42M | -11.30M | -33.22M | -33.20M | -36.03M | 9.34M | -2.99M | 1.24M | -1.89M | -14.99M | -5.79M | -8.25M | -8.30M | -8.10M |
| EBITDA Ratio | -533.29% | 0.00% | 0.00% | -141.52% | -24.22% | -51.44% | 37.39% | 39.14% | 66.70% | -123.76% | -95.02% | -139.41% | -30.64% | -28.24% | -27.64% | -29.72% | -93.83% | -142.19% | -175.99% | 20.77% | -12.30% | -6.47% | -14.82% | -137.98% | -53.73% | -85.84% | -111.11% | -179.59% |
| Operating Income | -137.85M | -98.56M | -85.55M | -36.66M | -16.83M | -104.93M | 88.30M | -4.97M | 71.45M | -93.86M | -50.03M | -3.49M | -9.58M | -9.84M | -11.75M | -20.16M | -40.85M | -38.84M | -40.77M | 8.84M | -4.70M | -223.00K | -3.16M | -16.11M | -7.00M | -9.29M | -9.00M | -9.00M |
| Operating Income Ratio | -492.97% | 0.00% | 0.00% | -164.15% | -28.42% | -101.60% | 51.12% | -3.30% | 41.25% | -635.24% | -222.93% | -13.36% | -29.40% | -26.53% | -27.90% | -52.20% | -111.44% | -168.71% | -172.76% | 15.94% | -18.67% | -1.21% | -24.11% | -147.74% | -63.41% | -97.57% | -111.11% | -183.67% |
| Total Other Income/Expenses | -22.93M | -12.88M | -7.60M | -10.90M | -14.47M | -8.27M | 3.16M | -4.75M | 6.26M | 3.33M | -4.06M | 1.98M | 1.00M | 1.07M | 314.00K | 1.60M | 1.42M | 1.52M | 9.11M | 463.00K | 272.00K | 2.68M | 295.00K | 11.27M | 322.00K | 232.00K | 800.00K | 600.00K |
| Income Before Tax | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M | -113.20M | 91.47M | -9.72M | 78.39M | -90.33M | -54.10M | -7.93M | -8.58M | -8.77M | -11.44M | -18.56M | -39.43M | -37.32M | -31.66M | 9.30M | -4.00M | 2.45M | -2.86M | -4.83M | -6.68M | -9.06M | -8.20M | -8.40M |
| Income Before Tax Ratio | -574.96% | 0.00% | 0.00% | -22.75% | -65.16% | -109.61% | 52.95% | -6.47% | 45.26% | -611.38% | -241.03% | -30.38% | -26.33% | -23.63% | -27.16% | -48.06% | -107.58% | -162.12% | -134.18% | 16.78% | -15.88% | 13.32% | -21.85% | -44.34% | -60.49% | -95.14% | -101.23% | -171.43% |
| Income Tax Expense | -501.00K | 26.03M | -15.82M | -12.11M | -5.36M | -17.89M | 24.22M | 31.56M | 37.74M | -1.41M | -11.17M | -4.70M | 192.00K | 209.00K | -6.23M | -6.48M | -1.69M | -2.12M | -4.29M | -3.20M | -503.00K | -553.00K | 14.00K | 50.00K | 16.00K | -1.25M | -1.40M | -1.50M |
| Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 67.25M | -41.28M | 40.66M | -84.91M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.49M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
| Net Income Ratio | -573.17% | 0.00% | 0.00% | 31.47% | -56.11% | -92.29% | 38.93% | -27.47% | 23.47% | -574.66% | -191.26% | -12.37% | -26.91% | -24.20% | -27.16% | -31.29% | -102.95% | -152.91% | -116.01% | 22.56% | -13.88% | 16.33% | -21.96% | -86.78% | -60.63% | -82.04% | -83.95% | -140.82% |
| EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.58 | -0.20 | 0.19 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| EPS Diluted | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.61 | -1.00 | 0.93 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.53 | -0.20 | 0.18 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| Weighted Avg Shares Out | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M | 37.33M | 40.47M | 41.25M | 40.58M | 36.21M | 25.41M | 24.95M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 21.51M | 17.76M | 16.20M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
| Weighted Avg Shares Out (Dil) | 80.17M | 60.09M | 58.54M | 54.94M | 37.40M | 37.33M | 41.77M | 41.25M | 43.62M | 36.21M | 25.45M | 25.09M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 23.56M | 17.76M | 16.71M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today...
Avadel Pharmaceuticals: Looking Good For Investors And Patients With Narcolepsy
Avadel's flagship compound, FT218, is on its way towards approval with the FDA. FT218 once nightly dose has been proven more efficient and better accepted by patients than competing products.
Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that...
3 Fast-Growing Small Caps to Consider
Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the...
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that...
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports